Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Cloud – page 230

3 344 clinical trials in Saint-Cloud, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Cloud at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Saint-Cloud

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

B-cell small lymphocytic lymphoma

Not recruiting

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Advanced systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Cogent Biosciences Inc.

Breast cancer metastatic+2

Not recruiting

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Institut Jules Bordet

Ovarian cancer

Not recruiting

Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Adenocarcinoma gastric

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Bladder transitional cell carcinoma

Not recruiting

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Acute myeloid leukaemia

Not recruiting

Study on S65487 and Azacitidine for Adults with Untreated Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Dementia with Lewy bodies

Not recruiting

Study on Neflamapimod for Patients with Dementia with Lewy Bodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Neflamapimod
  • Sponsor:Eip Pharma Inc.

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

  • B-Cell Lymphomas
  • Multiple Myeloma
  • T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

  • HR+/HER2- Advanced Breast Cancer
  • Triple-Negative Breast Cancer
  • Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

  • Lung Cancer
  • Biliary Tract Cancer
  • Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.